Navigation Links
Delcath Announces First CHEMOSAT Procedures in Germany
Date:2/27/2012

the hospital's strong academic approach. This makes sure that patients coming to the University Hospital for treatment enjoy the benefits resulting from timely implementation of research findings. Every year, around 47,200 and 220,000 patients respectively receive in- and outpatient treatment. The University Hospital possesses special interdisciplinary competence in the fields of neurological science, oncology and cardiovascular medicine.

About Delcath Systems

Delcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival.  The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , June 29, 2015 ... addition of the "Pharmaceutical Grade Sodium Chloride Market ... to 2019" report to their offering. ... witness a CAGR of 6.9% between 2014 and 2019 ... to reach 690 KT by 2019. The ...
(Date:7/6/2015)... BOULDER, Colo. , July 6, 2015 /PRNewswire/ ... inhibitor, encorafenib, was showcased this past weekend at ... during an oral presentation.  At the meeting, data ... preliminary data from a 100-patient randomized Phase 2 ... encorafenib and cetuximab, an EGFR inhibitor, with or ...
(Date:7/6/2015)...   Cepheid (Nasdaq: CPHD ) today announced ... second quarter ended June 30, 2015 on Thursday, July ... The Company will host a management presentation at ... to discuss the results.  To access the live webcast, ... least 15 minutes before the scheduled start time to ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4
... mental retardation, birth defects, and autism spectrum and ... in New YorkMADISON, N.J., March 17 Quest ... world,s leading provider of diagnostic testing, information and ... genomic hybridization (aCGH) postnatal test is now available ...
... Inc. announced today that it has achieved proof ... Inhibiting Multiple Pathways) kinase platform by designing a ... of both the PI3K (Phosphoinositide-3-kinase) pathway and the ... SF2626 has demonstrated the ability to inhibit both ...
Cached Medicine Technology:Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 2Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 3Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 4Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor 2
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer Hope Network (CHN) has ... medical professionals to chat with the CHN patient services team and connect with ... diagnosis is often the most traumatic experience of a person’s life,” said CHN ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... & Associates has once again teamed up with Family Emergency Shelter Coalition (FESCO) ... move toward self-sufficiency. FESCO was created especially to provide emergency services and support ...
(Date:7/6/2015)... ... 06, 2015 , ... With a new community program in the Livonia, Canton ... and announced a new charity campaign to raise funds in support of the health ... Livonia Save Our Youth is a coalition created especially to educate and empower teens, ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Dr. Lawrence ... Washington, DC, area patients. Kybella is a non-surgical method to dissolve fat ... of reducing moderate to severe fat deposits under the chin, commonly known as a ...
(Date:7/6/2015)... Kingdom (PRWEB) , ... July 06, 2015 , ... Diabetes ... could help. More than 29 million Americans have diabetes, the majority of which are ... million U.S. adults or more than one in three, have prediabetes (abnormally high blood ...
Breaking Medicine News(10 mins):Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2
... people "tear up," but a new study led by University of ... containing an ingredient derived from hot chili peppers ( Capsicum annum ... The study, which appears in the August 2011 edition ... use of the Capsicum annum nasal spray to a ...
... cyclase C (GCC) has been established as a suppressor ... Thomas Jefferson University suggests it may also help ... Reporting in the August 25 online issue of ... M.D., Ph.D., chairman of the Department of Pharmacology ...
... HealthDay Reporter , THURSDAY, Aug. 25 (HealthDay News) -- An ... finds that children,s vaccines are typically safe, with bad reactions ... problems. The IOM committee also agreed that there is ... later onset of conditions such as autism or type 1 ...
... Aug. 24, 2011 -- Heart rate and blood pressure ... in children. In a new study by researchers at Wake ... a condition known as orthostatic intolerance (OI), which causes dizziness ... shown to reduce debilitating chronic nausea in patients., "There seems ...
... , WASHINGTON An analysis of more than 1,000 ... by or clearly associated with vaccines. A committee ... review the scientific literature on possible adverse effects of ... including seizures, inflammation of the brain, and fainting -- ...
... THURSDAY, Aug. 25 (HealthDay News) -- Federal officials on Thursday ... make emergency preparations for Hurricane Irene, a "category 3" storm ... current forecast places the center of Irene just off the ... Monday morning, according to the U.S. National Weather Service. ...
Cached Medicine News:Health News:Could a tumor suppressor also fight obesity? 2Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 2Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 3Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 4Health News:Heart may hold key to unexplained nausea in youths 2Health News:Few health problems are caused by vaccines, IOM report finds 2Health News:Few health problems are caused by vaccines, IOM report finds 3Health News:East Coast Urged to Prepare as Hurricane Irene Approaches 2
White Standard Girdle...
Below Knee Girdle, High Waist...
Bodyshaper For Men...
Torso Brief Bodysuit V-BA85...
Medicine Products: